Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.
Approval Alert | Tislelizumab/Chemotherapy in Unresectable or Metastatic PD-L1+ ESCC
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
